Favorable survival for older adults treated with Axi-cel and Tisa-cel CD19 CAR-T therapy for relapsed/refractory DLBCL: a U.S. multicenter comparative analysis. (PubMed, Transplant Cell Ther) - Oct 20, 2026 - "Data from our Cell Therapy Consortium retrospective analysis demonstrate that CAR-T recipients older than 65 yrs experience favorable outcomes and manageable toxicity similar to younger patients. Our results support the practice that age alone should not be a barrier to CAR-T consultation or therapy."
Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
David L Porter; Joseph P McGuirk; Marie Hu; Michael R Bishop; Miguel-Angel Perales; Olalekan O Oluwole; Paolo Strati; Peter A Riedell; Qing Cao; Richard T Maziarz; Sairah Ahmed; Smith Kungwankiattichai; Stephen J Schuster; Veronika Bachanova
|